Aligos Therapeutics (ALGS) Enterprise Value (2021 - 2025)
Historic Enterprise Value for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to -$156.2 million.
- Aligos Therapeutics' Enterprise Value fell 3647.36% to -$156.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$156.2 million, marking a year-over-year decrease of 3647.36%. This contributed to the annual value of -$56.9 million for FY2024, which is 5807.27% up from last year.
- According to the latest figures from Q3 2025, Aligos Therapeutics' Enterprise Value is -$156.2 million, which was down 3647.36% from -$227.2 million recorded in Q2 2025.
- In the past 5 years, Aligos Therapeutics' Enterprise Value registered a high of -$56.9 million during Q4 2024, and its lowest value of -$242.2 million during Q3 2021.
- Over the past 5 years, Aligos Therapeutics' median Enterprise Value value was -$156.2 million (recorded in 2025), while the average stood at -$155.3 million.
- The largest annual percentage gain for Aligos Therapeutics' Enterprise Value in the last 5 years was 5807.27% (2024), contrasted with its biggest fall of 9445.11% (2024).
- Aligos Therapeutics' Enterprise Value (Quarter) stood at -$190.7 million in 2021, then skyrocketed by 34.03% to -$125.8 million in 2022, then fell by 7.93% to -$135.8 million in 2023, then skyrocketed by 58.07% to -$56.9 million in 2024, then plummeted by 174.42% to -$156.2 million in 2025.
- Its Enterprise Value stands at -$156.2 million for Q3 2025, versus -$227.2 million for Q2 2025 and -$202.0 million for Q1 2025.